This is what real oncology therapeutics looks like...

Discussion in 'Amgen' started by anonymous, Sep 26, 2015 at 2:12 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    SURVIVAL IS WHAT TRUE THERAPEUTICS DO OBU...FUCKING LOSERS!!!!


    Bristol's Opdivo boosts kidney cancer survival beyond two years

    * Opdivo survival 25 months vs 19.6 for Afinitor - study


    * Sets up drug to be used beyond melanoma and lung cancer

    By Ben Hirschler

    Sept 26 (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo extended kidney cancer survival rates by more than two years in a late-stage trial, setting it up to be used beyond melanoma and lung cancer.

    The U.S. company said in July the study was stopped early because its drug was more effective than Novartis' established product Afinitor, but detailed results were only disclosed at the European Cancer Congress in Vienna on Saturday.

    The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer
    • Opdivo is already approved for melanoma and lung cancer, with most attention focused on the big lung cancer opportunity. But analysts noted that RCC prevalence was twice that of melanoma, pointing to significant commercial upside
     

  2. anonymous

    anonymous Guest

    wow were you the scientist who created Opdivo? Are you the CEO of bristol? Do you own the rights ?? You seem so excited .. Anyway of the answer is no to the above questions that shut your mouth and who cares.. We're all reps and can can get laid off at any time so why beat your chest for something you have absolutely nothing to do with ...
     
  3. anonymous

    anonymous Guest

    Loser OBU

    You don't get it. It's a true onc rep thing.

    Signed,

    Onyx
     
  4. anonymous

    anonymous Guest

    BMS #1
     
  5. anonymous

    anonymous Guest

    Amgen OBU is PRIMARY CARE!
     
  6. anonymous

    anonymous Guest

    Vectibix has overall survival of 23.8 months when used in combo with FOLFOX, which is an additional 4.4 months, compared to FOLFOX alone.

    In monotherapy, 10.4 months of OS with Vectibix. Not to mention, this is a targeted therapy for mCRC.

    Now, stop coming on OUR board and trashing us. You must have a Napoleon complex little man. Someone who feels confident in what they sell and their abilities doesn't need to go on ANOTHER company's site to trash them. This makes you the LOSER.